Shanghai Rightongene Financials
| 688217 Stock | 19.59 0.01 0.05% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 301.2 K | 317 K |
|
|
Shanghai | Select Account or Indicator |
Understanding current and past Shanghai Rightongene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Shanghai Rightongene's financial statements are interrelated, with each one affecting the others. For example, an increase in Shanghai Rightongene's assets may result in an increase in income on the income statement.
Please note, the presentation of Shanghai Rightongene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Shanghai Rightongene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Shanghai Rightongene's management manipulating its earnings.
Shanghai Rightongene Stock Summary
Shanghai Rightongene competes with Xiandai Investment, Tsingtao Brewery, Bus Online, Easyhome New, and Shuhua Sports. Shanghai Rightongene is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| Business Address | No 147, Lane |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.rightongene.com |
| Phone | 86 21 3328 2601 |
You should never invest in Shanghai Rightongene without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Shanghai Stock, because this is throwing your money away. Analyzing the key information contained in Shanghai Rightongene's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Shanghai Rightongene Key Financial Ratios
Shanghai Rightongene's financial ratios allow both analysts and investors to convert raw data from Shanghai Rightongene's financial statements into concise, actionable information that can be used to evaluate the performance of Shanghai Rightongene over time and compare it to other companies across industries.| Revenue | 258.21 M | ||||
| Gross Profit | 182.74 M | ||||
| EBITDA | 25.94 M | ||||
| Net Income | 7.93 M | ||||
| Total Asset | 1.04 B |
Shanghai Rightongene Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 722.9M | 947.5M | 1.1B | 1.0B | 1.2B | 979.9M | |
| Other Current Liab | 4.5M | 2.7M | 2.0M | 2.6M | 2.4M | 2.8M | |
| Retained Earnings | 68.3M | 115.7M | 156.2M | 154.0M | 177.1M | 115.2M | |
| Accounts Payable | 12.3M | 11.2M | 51.2M | 14.4M | 16.5M | 24.5M | |
| Cash | 142.0M | 123.4M | 203.9M | 161.7M | 185.9M | 167.0M | |
| Net Receivables | 164.3M | 163.7M | 255.8M | 187.2M | 215.3M | 205.5M | |
| Inventory | 27.1M | 37.3M | 54.0M | 60.7M | 69.8M | 47.3M | |
| Other Current Assets | 25.9M | 10.0M | 6.3M | 14.1M | 12.7M | 13.1M | |
| Total Liab | 61.1M | 50.9M | 112.4M | 76.5M | 88.0M | 76.7M | |
| Net Invested Capital | 650.3M | 893.5M | 941.2M | 967.9M | 1.1B | 893.4M | |
| Total Current Assets | 388.6M | 556.3M | 624.5M | 509.9M | 586.4M | 540.0M | |
| Net Working Capital | 347.5M | 522.9M | 534.4M | 467.3M | 537.4M | 485.6M | |
| Intangible Assets | 44.9M | 46.4M | 40.0M | 49.6M | 57.1M | 48.1M |
Shanghai Rightongene Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 1.3M | 2.4M | 5.6M | (4.6M) | (4.1M) | (3.9M) | |
| Net Interest Income | 1.2M | 2.0M | 1.6M | 2.9M | 3.3M | 2.2M | |
| Interest Income | 1.4M | 2.6M | 2.2M | 3.8M | 4.4M | 2.8M | |
| Interest Expense | 61.0K | 491.8K | 549.8K | 828.5K | 952.8K | 1.0M | |
| Total Revenue | 284.9M | 291.0M | 424.3M | 258.2M | 296.9M | 333.1M | |
| Gross Profit | 204.7M | 212.7M | 258.0M | 189.0M | 217.4M | 235.5M | |
| Operating Income | 45.0M | 34.2M | 86.3M | 352.3K | 317.0K | 301.2K | |
| Research Development | 74.4M | 68.6M | 64.4M | 69.8M | 62.8M | 55.1M | |
| Cost Of Revenue | 80.2M | 78.2M | 166.3M | 69.2M | 79.5M | 97.6M | |
| Income Before Tax | 40.1M | 42.4M | 71.5M | (9.4M) | (8.5M) | (8.0M) | |
| Net Income | 38.7M | 47.3M | 40.5M | 7.9M | 7.1M | 6.8M |
Shanghai Rightongene Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Shanghai Rightongene. It measures of how well Shanghai is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Shanghai Rightongene brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Shanghai had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Shanghai Rightongene has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 8.0M | (10.8M) | (17.0M) | (15.9M) | (14.3M) | (15.1M) | |
| Investments | (49.3M) | (278.6M) | 7.0M | (102.6M) | (92.3M) | (96.9M) | |
| Change In Cash | 5.3M | (10.3M) | 80.3M | (45.3M) | (52.1M) | (49.5M) | |
| Free Cash Flow | 18.0M | (17.6M) | (33.5M) | (64.0M) | (57.6M) | (54.7M) | |
| Change In Working Capital | (7.7M) | (3.9M) | (57.0M) | (8.5M) | (9.8M) | (10.3M) | |
| Begin Period Cash Flow | 128.0M | 133.3M | 122.9M | 203.2M | 233.6M | 164.5M | |
| Depreciation | 28.4M | 37.5M | 35.7M | 44.4M | 51.1M | 36.5M | |
| Other Non Cash Items | 8.9M | 6.0M | (1.5M) | 1.2M | 1.1M | 998.3K | |
| Capital Expenditures | 52.1M | 95.6M | 106.6M | 109.1M | 125.5M | 91.8M | |
| Total Cash From Operating Activities | 70.1M | 78.0M | 73.1M | 45.1M | 51.9M | 61.1M | |
| Net Income | 38.7M | 47.3M | 40.5M | 7.9M | 7.1M | 6.8M | |
| End Period Cash Flow | 133.3M | 122.9M | 203.2M | 157.9M | 181.6M | 163.9M |
Shanghai Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Rightongene's current stock value. Our valuation model uses many indicators to compare Shanghai Rightongene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shanghai Rightongene competition to find correlations between indicators driving Shanghai Rightongene's intrinsic value. More Info.Shanghai Rightongene Biotechnology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Shanghai Rightongene by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shanghai Rightongene's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Shanghai Rightongene Systematic Risk
Shanghai Rightongene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Shanghai Rightongene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Shanghai Rightongene correlated with the market. If Beta is less than 0 Shanghai Rightongene generally moves in the opposite direction as compared to the market. If Shanghai Rightongene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Shanghai Rightongene is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Shanghai Rightongene is generally in the same direction as the market. If Beta > 1 Shanghai Rightongene moves generally in the same direction as, but more than the movement of the benchmark.
Shanghai Rightongene Biotechnology Total Assets Over Time
Shanghai Rightongene Thematic Clasifications
Shanghai Rightongene Biotechnology is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Shanghai Rightongene January 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Shanghai Rightongene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Shanghai Rightongene Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Shanghai Rightongene Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Shanghai Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Shanghai Rightongene's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.25 | |||
| Information Ratio | 0.059 | |||
| Maximum Drawdown | 24.78 | |||
| Value At Risk | (5.23) | |||
| Potential Upside | 5.4 |
Complementary Tools for Shanghai Stock analysis
When running Shanghai Rightongene's price analysis, check to measure Shanghai Rightongene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Rightongene is operating at the current time. Most of Shanghai Rightongene's value examination focuses on studying past and present price action to predict the probability of Shanghai Rightongene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Rightongene's price. Additionally, you may evaluate how the addition of Shanghai Rightongene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |